MRM Health a clinicalstage biopharmaceutical company announced today that it has received regulatory and ethics committee approval to start an observational crosssectional clinical trial to study the role of the small intestinal microbiome in Parkinsons Disease PD and to identify PDspecific microbial and metabolic fingerprints in small intestinal fluid and blood.
MRM Health NV a clinicalstage biopharmaceutical company focused on developing nextgeneration live microbiome consortia therapeutics today reports positive topline results from its Phase 2a clinical trial with MH002 in mildtomoderate Ulcerative Colitis UC.
GHENT, Belgium, June 28, 2022 (GLOBE NEWSWIRE) MRM Health, a clinical-stage biopharmaceutical company developing next-generation live microbiome consortia therapeutics, announced today that they have
MRM Health Starts Clinical Trial with Next-Generation Optimized Consortium Therapeutic MH002 in Pouchitis GlobeNewswire June 28, 2022 GHENT, Belgium, June 28, 2022 (GLOBE NEWSWIRE) MRM Health, a clinical-stage biopharmaceutical company developing next-generation live microbiome consortia therapeutics, announced today that they have received regulatory approval from the Federal Agency for Medicines and.
GHENT, Belgium, June 07, 2022 (GLOBE NEWSWIRE) MRM Health, a clinical-stage biopharmaceutical company developing next-generation live microbiome consortia therapeutics, announces the publication of